Scarica l'app Stockscreener
7.69
0.79%
0.06
Pre-mercato:
8.10
0.41
+5.33%
Precedente Chiudi:
$7.63
Aprire:
$7.7
Volume 24 ore:
24,226
Relative Volume:
1.42
Capitalizzazione di mercato:
$37.22M
Reddito:
$1.28M
Utile/perdita netta:
$280.60K
Rapporto P/E:
-96.12
EPS:
-0.08
Flusso di cassa netto:
-
1 W Prestazione:
-3.27%
1M Prestazione:
-19.98%
6M Prestazione:
-17.49%
1 anno Prestazione:
-19.90%
Intervallo 1D:
$7.60
$7.7499
Intervallo di 1 settimana:
$7.56
$8.202
Portata 52W:
$7.19
$10.04
Daxor Corporation Stock (DXR) Company Profile
Nome
Daxor Corporation
Settore
Industria
Telefono
212-330-8500
Indirizzo
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Confronta DXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.69 | 37.22M | 1.28M | 280.60K | 0 | -0.7197 |
|
ISRG
Intuitive Surgical Inc
|
521.96 | 185.91B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
226.87 | 65.59B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.89 | 41.99B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
228.69 | 33.57B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
327.56 | 23.72B | 2.88B | 499.60M | 321.60M | 6.74 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-16 | Iniziato | Ascendiant Capital Markets | Buy |
Daxor Corporation Borsa (DXR) Ultime notizie
Daxor (NYSEAMERICAN:DXR) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Daxor (NASDAQ:DXR) Shares Up 0.8% – Should You Buy? - Defense World
When (DXR) Moves Investors should Listen - Stock Traders Daily
Reviewing Embecta (NASDAQ:EMBC) and Daxor (NASDAQ:DXR) - Defense World
Daxor (NYSEAMERICAN:DXR) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
(DXR) Long Term Investment Analysis - Stock Traders Daily
Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - GlobeNewswire
Daxor Expands Blood Analysis Service to Major Health Networks, Reports Record-Breaking Quarter - StockTitan
Daxor Expands Its BVA-100?? Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - Marketscreener.com
Daxor corp CEO Michael Feldschuh acquires 45,000 shares By Investing.com - Investing.com Nigeria
Daxor corp CFO Michel acquires 4,750 shares at no cost By Investing.com - Investing.com Nigeria
Daxor's chief scientific officer acquires 32,000 shares By Investing.com - Investing.com Canada
Daxor's chief scientific officer acquires 32,000 shares - Investing.com
Daxor corp CFO Michel acquires 4,750 shares at no cost - Investing.com
Daxor corp CEO Michael Feldschuh acquires 45,000 shares - Investing.com
How the (DXR) price action is used to our Advantage - Stock Traders Daily
Daxor (NYSEAMERICAN:DXR) Stock Price Down 2.1% – Time to Sell? - Defense World
Daxor (NASDAQ:DXR) & Co-Diagnostics (NASDAQ:CODX) Critical Survey - Defense World
(DXR) On The My Stocks Page - Stock Traders Daily
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - The Manila Times
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC - GlobeNewswire
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Long Term Trading Analysis for (DXR) - Stock Traders Daily
Short Interest in Daxor Co. (NASDAQ:DXR) Rises By 39.6% - Defense World
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device - The Manila Times
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - GlobeNewswire
Daxor (NYSEAMERICAN:DXR) Stock Passes Above Two Hundred Day Moving Average of $0.00 - Defense World
(DXR) Technical Data - Stock Traders Daily
Daxor announces review published in journal on BVA - TipRanks
Newly Published Review Highlights the Pivotal Role of - GlobeNewswire
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management - StockTitan
Daxor (NASDAQ:DXR) Price Target Raised to $24.75 at Ascendiant Capital Markets - Defense World
Daxor secures $300K from LaunchTN for blood analyzer tech - Investing.com India
Daxor receives $300K matching fund award from Launch Tennessee - TipRanks
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee - GlobeNewswire
DXRDaxor Corporation Latest Stock News & Market Updates - StockTitan
Central Florida hospital implements Daxor BVA-100 blood volume diagnostic - TipRanks
Leading Central Florida Hospital Implements Daxor’s - GlobeNewswire
Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care - StockTitan
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter - GlobeNewswire
Daxor reports doubled revenue, secures government contracts - Investing.com
Daxor reports doubled revenue, secures government contracts By Investing.com - Investing.com Canada
Daxor CEO says NAV increased to $6.75 p/s from $6.33 last year this time - TipRanks
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network - GlobeNewswire
Daxor Corporation Azioni (DXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):